Loading...

TARGETING UNMET GLOBAL NEEDS IN MULTI-BILLION DOLLAR MARKETS

review our transforming drug-delivery platforms

Virpax® Pharmaceuticals Inc., (Nasdaq: VRPX) is a publicly held specialty pharmaceutical company located in Berwyn, PA and is focused on advancing the development and worldwide commercialization of its non-addictive pain and neurological disorder pipeline.

Virpax’s transforming drug-delivery platforms and their targeted drug-releasing capabilities have been developed to enhance compliance and to optimize the efficacy of our non-addictive pain management pipeline and our Central Nervous System (CNS) disorder pipeline.

Virpax’s non-addictive pain management pipeline is being developed in collaboration with the National Institute of Health (NIH) and the Department of Defense (DoD). We anticipate advancing two pain assets into human trials in 2024. Once approved, these pain management alternatives may provide treatment options that help patients achieve better health outcomes.

Virpax is traded on

(Nasdaq: VRPX)

View our presentation

OPTIMIZING NON-ADDICTIVE DRUG DELIVERY

IN THE MANAGEMENT OF PAIN AND CNS DISORDERS, INCLUDING RARE AND ORPHAN DISEASES

Probudur injection icon

Probudur™
Lead Product Candidate

Injectable liposomal Bupivacaine

Probudur is a next generation liposomal bupivacaine formulation that has demonstrated 96 hours pain control after administering a single injection at the wound site in animal studies.

Probudur injection icon

Probudur™ Lead Product Candidate

Injectable liposomal Bupivacaine

Probudur is a next generation liposomal bupivacaine formulation that has demonstrated 96 hours pain control after administering a single injection at the wound site in animal studies.

Envelta spray icon

Envelta™

Molecular Envelope Enkephalin Powder

Envelta is an innovative intranasal enkephalin powder formulation that has demonstrated an ability to control severe pain without exhibiting respiratory depression, drug seeking behavior and drug tolerance in animal studies compared to morphine.

VRP324 spray icon

NobrXiol™

Molecular Envelope Cannabidiol Powder

NobrXiol is an innovative pharmaceutical-grade cannabidiol intranasal spray powder being developed to manage Rare Pediatric Epilepsy without being metabolized by the liver; hence, avoiding drug to drug interactions caused by approved oral dosing.

Virpax is positioning its proprietary Rx pipeline to meet unmet needs in

three multi-billion dollar markets

OUR MISSION

Our purpose is to develop innovative delivery platform technologies that optimize patient care worldwide in non-addictive pain and neurological disorders.

OUR VISION

We aspire to be a leader in addressing patient and provider needs worldwide in the management of pain and neurological disorders.

“We’ve continued to support development of novel non-addictive treatments for pain, including non-opioid analgesics and medical devices.”

ROBERT CALIFF

FDA Commissioner
ADVANCINGNON-ADDICTIVEPAIN MANAGEMENTWORLDWIDE

Experienced

executive leadership

Robust

pipeline